ALGS Q1 2024 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$986,000-63.8% YoY

Gross Profit

$986,000100.0% margin

Operating Income

-$22M-2235.9% margin

Net Income

-$35M-3535.8% margin

EPS (Diluted)

$-2.24

QoQ Revenue Growth

-63.2%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$128M

Total Liabilities

$68M

Stockholders' Equity

$60M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$986,000	$3M	-63.8%
Gross Profit	$986,000	$3M	-63.8%
Operating Income	-$22M	-$24M	+7.8%
Net Income	-$35M	-$23M	-51.9%